Agomab Therapeutics, a Belgium-based developer of tissue regeneration technology based on research at University of Turin, has secured €21m ($23.8m) in series A funding from a consortium including pharmaceutical firm Boehringer Ingelheim.
The round was co-led by venture capital fund V-Bio Ventures and life sciences VC firm Advent France Biotechnology and included Omnes and Pontifax, while Boehringer Ingelheim invested through corporate venturing vehicle Boehringer Ingelheim Venture Fund (BIVF).
Founded in 2017, Agomab is developing antibodies for the regeneration of damaged tissue, with technology based on research by Paolo Michieli and his translational medicine team at University of Turin.
The company has also exercise an exclusive license agreement with Euronext and Nasdaq-listed peer Argenx to develop its antibodies.
Ilka Wicke, an investment manager at BIVF, has joined Agomab’s board of directors in connection with the latest round.
– A version of this article first appeared on our sister site, Global Corporate Venturing.

Agomab Therapeutics, a Belgium-based developer of tissue regeneration technology, has secured €21m ($23.8m) in series A funding from a consortium including pharmaceutical firm Boehringer Ingelheim.

The round was co-led by venture capital fund V-Bio Ventures and life sciences VC firm Advent France Biotechnology and included Omnes and Pontifax, while Boehringer Ingelheim invested through corporate venturing vehicle Boehringer Ingelheim Venture Fund (BIVF).

Founded in 2017, Agomab is developing antibodies for the regeneration of damaged tissue, with technology based on research by Paolo Michieli and his translational medicine team at the University of Torino.

The company has also exercise an exclusive license agreement with Euronext and Nasdaq-listed peer Argenx to develop its antibodies.

Ilka Wicke, an investment manager at BIVF, has joined Agomab’s board of directors in connection with the latest round.